Literature DB >> 25987695

Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better?

Kathleen N Moore1, Michelle R Rowland2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25987695     DOI： 10.1200/JCO.2015.61.0998

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Paip1 Indicated Poor Prognosis in Cervical Cancer and Promoted Cervical Carcinogenesis.

Authors:  Nan Li; Junjie Piao; Xinyue Wang; Ki-Yeol Kim; Jung Yoon Bae; Xiangshan Ren; Zhenhua Lin
Journal:  Cancer Res Treat       Date:  2019-04-19       Impact factor: 4.679

2.  Chemotherapy and molecular targeting therapy for recurrent cervical cancer.

Authors:  Naotake Tsuda; Hidemichi Watari; Kimio Ushijima
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

3.  LncRNA NCK1-AS1 promotes proliferation and induces cell cycle progression by crosstalk NCK1-AS1/miR-6857/CDK1 pathway.

Authors:  Haiyu Li; Yongqin Jia; Junning Cheng; Geli Liu; Fangzhou Song
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469

4.  Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target of cervical cancer.

Authors:  Juan Wang; Yamei Wang; Fangrong Shen; Yanting Xu; Yinghui Zhang; Xinwei Zou; Jinhua Zhou; Youguo Chen
Journal:  Cancer Med       Date:  2018-10-18       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.